Tyrosine kinase inhibitor-induced severe bullous pemphigoid in a patient
with advanced stage of liver cancer: a case report and literature review
Abstract
Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR2)
targeted chemotherapy for solid tumors, has revealed promising efficacy
in treating liver cancer in China. Although it has been reported to have
a high incidence of inducing hand-foot skin reactions, other skin
adverse reactions induced by apatinib are rare. Herein, we report a rare
case of apatinib-induced severe bullous dermatosis that was successfully
treated with methylprednisolone and summarize the dermatologic
toxicities of VEGFR tyrosine kinase inhibitor.